Charles is a Research Analyst at Vestal Point, primarily covering pre-commercial stage therapeutics. Before Vestal Point, Charles was an Analyst working alongside Ryan Wilder at Point72 from 2017 to 2023 focusing on pre-commercial biotechnology stocks.

Prior to Point72, he worked at JPMorgan Asset Management (2014-2017) and the Investment Banking Group at Barclays (2012-2014). Charles graduated from Cornell University with a B.S. in Finance and Statistics.